288 related articles for article (PubMed ID: 23870727)
1. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study.
Sacco R; Romano A; Mazzoni A; Bertini M; Federici G; Metrangolo S; Parisi G; Nencini C; Giampietro C; Bertoni M; Tumino E; Scatena F; Bresci G
J Crohns Colitis; 2013 Dec; 7(12):e692-7. PubMed ID: 23870727
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
Herrlinger KR; Diculescu M; Fellermann K; Hartmann H; Howaldt S; Nikolov R; Petrov A; Reindl W; Otte JM; Stoynov S; Strauch U; Sturm A; Voiosu R; Ammendola A; Dietrich B; Hentsch B; Stange EF
J Crohns Colitis; 2013 Sep; 7(8):636-43. PubMed ID: 23078909
[TBL] [Abstract][Full Text] [Related]
3. Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up.
Bresci G; Parisi G; Mazzoni A; Scatena F; Capria A
J Gastroenterol Hepatol; 2008 Nov; 23(11):1678-82. PubMed ID: 18823440
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
5. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
6. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis.
Naganuma M; Funakoshi S; Sakuraba A; Takagi H; Inoue N; Ogata H; Iwao Y; Ishi H; Hibi T
Inflamm Bowel Dis; 2004 May; 10(3):251-7. PubMed ID: 15290920
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
8. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
Domènech E; Hinojosa J; Esteve-Comas M; Gomollón F; Herrera JM; Bastida G; Obrador A; Ruiz R; Saro C; Gassull MA;
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1347-52. PubMed ID: 15606397
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study.
Martín de Carpi J; Vilar P; Prieto G; García Novo MD; Ribes C; Varea V
J Pediatr Gastroenterol Nutr; 2008 Apr; 46(4):386-91. PubMed ID: 18367949
[TBL] [Abstract][Full Text] [Related]
10. [Granulocytapheresis in inflammatory bowel disease. Efficacy of an induction plus maintenance sessions protocol at 32 weeks].
Fernández Pérez FJ; Rodríguez F; de Sola C; Fernández Moreno N; Vera F; Rivera R; Sánchez Cantos A
Rev Esp Enferm Dig; 2007 Nov; 99(11):628-35. PubMed ID: 18271660
[TBL] [Abstract][Full Text] [Related]
11. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study.
Passalacqua S; Ferraro PM; Bresci G; D'Ovidio V; Astegiano M; Principi M; Testa R; D'Incà R; Valpiani D; Armuzzi A; Sablich R; Cavallaro F; Costa F; Di Leo V; Colombo E; Santini A; Aratari A; Lecis P; Saladino V; Riegler G; Marco M; Calella F; Ricci C; Guidi ML; Repaci G; Silla M
J Clin Apher; 2011 Dec; 26(6):332-7. PubMed ID: 22072543
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives.
Ruuska T; Wewer V; Lindgren F; Malmborg P; Lindquist M; Marthinsen L; Browaldh L; Casswall T; Kalliomäki M; Grönlund J
Inflamm Bowel Dis; 2009 Jul; 15(7):1049-54. PubMed ID: 19137602
[TBL] [Abstract][Full Text] [Related]
13. Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use.
Subramanian S; Asher R; Weston W; Rimmer M; McConville A; Malin A; Jackson R; Collins P; Probert C; Dibb M; Rhodes JM
Inflamm Bowel Dis; 2016 Aug; 22(8):1902-7. PubMed ID: 27243590
[TBL] [Abstract][Full Text] [Related]
14. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study.
Giampaolo B; Giuseppe P; Michele B; Alessandro M; Fabrizio S; Alfonso C
World J Gastroenterol; 2006 Apr; 12(14):2201-4. PubMed ID: 16610021
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
[TBL] [Abstract][Full Text] [Related]
16. Adsorptive Monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease.
Kusaka T; Fukunaga K; Ohnishi K; Kosaka T; Tomita T; Yokoyama Y; Sawada K; Fukuda Y; Miwa H; Matsumoto T
J Clin Apher; 2004; 19(4):168-73. PubMed ID: 15597346
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
18. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
19. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
Bokemeyer B; Hardt J; Hüppe D; Prenzler A; Conrad S; Düffelmeyer M; Hartmann P; Hoffstadt M; Klugmann T; Schmidt C; Weismüller J; Mittendorf T; Raspe H
J Crohns Colitis; 2013 Jun; 7(5):355-68. PubMed ID: 22503168
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
Tursi A; Mocci G; Faggiani R; Allegretta L; Valle ND; Medici A; Forti G; Franceschi M; Ferronato A; Gallina S; Grasso G; Larussa T; Luzza F; Lorenzetti R; Penna A; Rodino' S; Sebkova L; Lauria A; Piergallini S; Pranzo G; Scorza S; Zampaletta C; Picchio M; Elisei W
Eur J Intern Med; 2019 Aug; 66():85-91. PubMed ID: 31208827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
